210 related articles for article (PubMed ID: 17903182)
1. Adjuvant conversion to sirolimus in liver transplant patients with recurrent hepatocellular carcinoma - preliminary results.
Kornberg A; Küpper B; Tannapfel A; Thrum K; Wilberg J; Bärthel E; Settmacher U
Transpl Int; 2008 Jan; 21(1):96-9. PubMed ID: 17903182
[No Abstract] [Full Text] [Related]
2. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity?
Perricone G; Mancuso A; Belli LS; Mazzarelli C; Zavaglia C
Eur J Gastroenterol Hepatol; 2014 May; 26(5):577-8. PubMed ID: 24694739
[No Abstract] [Full Text] [Related]
3. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria.
Zhou J; Wang Z; Wu ZQ; Qiu SJ; Yu Y; Huang XW; Tang ZY; Fan J
Transplant Proc; 2008 Dec; 40(10):3548-53. PubMed ID: 19100435
[TBL] [Abstract][Full Text] [Related]
4. Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation.
Heckman JT; Devera MB; Marsh JW; Fontes P; Amesur NB; Holloway SE; Nalesnik M; Geller DA; Steel JL; Gamblin TC
Ann Surg Oncol; 2008 Nov; 15(11):3169-77. PubMed ID: 18696158
[TBL] [Abstract][Full Text] [Related]
5. Decreased rate of growth of hepatocellular carcinoma recurrence after liver transplantation in patients maintained on cyclosporine immunosuppression.
O'Grady JG; Johnson PJ; Zaman S; Calne RY; Williams R
Transplant Proc; 1988 Jun; 20(3 Suppl 3):394-6. PubMed ID: 2838941
[No Abstract] [Full Text] [Related]
6. [Recurrence and metastasis of hepatocellular carcinoma after liver transplantation: single center experiences].
Zheng SS; Chen J; Wang WL; Zhang M; Shen Y; Wu J; Xu X; Yan S
Zhonghua Wai Ke Za Zhi; 2008 Nov; 46(21):1609-13. PubMed ID: 19094751
[TBL] [Abstract][Full Text] [Related]
7. Unusual presentation of recurrent hepatocellular carcinoma as obstructive jaundice 15 years after liver transplant.
Camci C; Gurakar A; Kohli V; Sharma S; Jabbour N
Exp Clin Transplant; 2007 Dec; 5(2):713-5. PubMed ID: 18194129
[TBL] [Abstract][Full Text] [Related]
8. Treatment for the recurrence of hepatocellular carcinoma following liver transplantation: what is the best strategy?
Shi YH; Zhou J; Fan J
Cancer Biol Ther; 2009 Apr; 8(7):22-4. PubMed ID: 19417558
[No Abstract] [Full Text] [Related]
9. Recurrence of hepatocellular carcinoma after liver transplantation presenting with massive intrahepatic bleeding.
Donadon M; Giacomoni A; Lauterio A; Slim A; Pirotta V; Mangoni I; De Carlis L
Liver Transpl; 2008 Feb; 14(2):259-61. PubMed ID: 18236411
[No Abstract] [Full Text] [Related]
10. Tumor size remains key for prediction of hepatocellular carcinoma recurrence after liver transplantation.
Earl TM; Chapman WC
Ann Surg Oncol; 2011 May; 18(5):1217-8. PubMed ID: 21327456
[No Abstract] [Full Text] [Related]
11. Safety of an immunosuppressant protocol based on sirolimus in liver transplant recipients with malignancies or high risk of tumor recurrence.
Castroagudín JF; Molina E; Tomé S; Otero E; Rodríguez M; Varo E
Transplant Proc; 2009 Apr; 41(3):1003-4. PubMed ID: 19376410
[TBL] [Abstract][Full Text] [Related]
12. [Liver transplantation for hepatocellular carcinoma and potential application of PSI].
Decaens T; Duvoux C
Gastroenterol Clin Biol; 2009 Nov; 33 Suppl 4():S257-62. PubMed ID: 20004332
[TBL] [Abstract][Full Text] [Related]
13. Liver transplant for hepatocellular carcinoma: experience in a Saudi population.
Allam N; Khalaf H; Fagih M; Al-Sebayel M
Exp Clin Transplant; 2008 Mar; 6(1):14-24. PubMed ID: 18405240
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation.
Chapman WC; Majella Doyle MB; Stuart JE; Vachharajani N; Crippin JS; Anderson CD; Lowell JA; Shenoy S; Darcy MD; Brown DB
Ann Surg; 2008 Oct; 248(4):617-25. PubMed ID: 18936575
[TBL] [Abstract][Full Text] [Related]
15. Hepatocellular cancer, transplantation, and sirolimus.
Wall WJ
Liver Transpl; 2004 Oct; 10(10):1312-4. PubMed ID: 15376337
[No Abstract] [Full Text] [Related]
16. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators.
Zimmerman MA; Ghobrial RM; Tong MJ; Hiatt JR; Cameron AM; Hong J; Busuttil RW
Arch Surg; 2008 Feb; 143(2):182-8; discussion 188. PubMed ID: 18283144
[TBL] [Abstract][Full Text] [Related]
17. Impressive regression of primary liver cancer after treatment with sirolimus.
Rizell M; Cahlin C; Friman S; Hafström L; Lönn L; Olausson M; Lindner P
Acta Oncol; 2005; 44(5):496. PubMed ID: 16118084
[No Abstract] [Full Text] [Related]
18. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
[TBL] [Abstract][Full Text] [Related]
19. Management of hepatocellular carcinoma.
Said A; Wells J
Minerva Med; 2009 Feb; 100(1):51-68. PubMed ID: 19277004
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus therapy in liver transplant patients: an initial experience at a single center.
Nocera A; Andorno E; Tagliamacco A; Morelli N; Bottino G; Ravazzoni F; Casaccia M; Barocci S; Alice S; Santori G; Ghirelli R; Valente U
Transplant Proc; 2008; 40(6):1950-2. PubMed ID: 18675098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
